GPC3 and hepatocellular carcinoma: GPC3 has been indicated as a prognostic marker for HCC, suggesting that GPC3 is a rational immunotherapeutic target for HCC.83 In March 2015, a group from Renji Hospital registered China’s first and the world’s first phase I clinical trial using CAR T-GPC3 to treat HCC.